Skip to main content
OpenTrials
Completed

NCT Number: NCT01227317

BIOmarkers of Dyspnea IN Emergency Room

The purpose of this study is to evaluate the capacity of some novels biomarkers Procalcitonin (PCT), Midregional Proadrenomedullin (MR pro ADM), Midregional pro-atrial natriuretic peptide (MR pro ANP), Copeptin (CT pro arginine vasopressin), Pro endothelin to stratify the risk in severe dyspnea.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Severe Dyspnea AE COPD Acute Heart Failure CAPD Cardiovascular Diseases Dyspnea Embolism Embolism and Thrombosis Lung Diseases Pathological Conditions, Signs and Symptoms Pulmonary Embolism Respiration Disorders Respiratory Tract Diseases Signs and Symptoms Signs and Symptoms, Respiratory Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Emergency department of Pitié Salpetriere Hospital

Paris, 75013, France

About this study

In emergency department shortness of breath (SOB)is a common symptom and its cause is not easy to be identified. The risk stratifying remains a challenge, Prognostic value of biomarkers might be helpful.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • tachypnea > 25 /min or Pa02 < 70 mmHg or SpO2 < 93%
  • diagnosis suspected: CAP, PE,EACOPD, AHF

Exclusion criteria

  • other cause of dyspnea,
  • unreachable on Day 30

Treatment and study plan

Prognostic value of Biomarkers

Other

Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients

Other names: Dyspnea, Prognostic value

Primary outcomes

  1. prognostic value of PCT, MR proADM, Mr pro ANP, Copeptin and pro endothelin in SOB

    Time frame: at Day 30

    all cause mortality or Intensive Care Unit(ICU) admission from inclusion to Day 30

Secondary outcomes

  1. establish the diagnostic value of PCT and MR pro ANP

    Time frame: at admission

    Confirm the diagnostic value of PCT and it's level in sepsis and MR pro ANP in Heart failure

Sponsors and collaborators

Lead sponsor

ThermoFisher Scientific Brahms Biomarkers France

Industry

Registry information

Official study title

Prognostic Value of Novel Biomarkers in Patients With Shortness of Breath Attending an Emergency Department

Acronym: BIODINER

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Oct 25, 2010
Registry last updated
Dec 7, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.